Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

Abstract

Objective To evaluate the addition of methylxanthines to standard treatments in patients presenting with acute exacerbations of chronic obstructive pulmonary disease (COPD). Design Meta-analysis of randomised controlled trials. Data source The Cochrane airways review group's COPD register. Two reviewers independently selected articles for inclusion, assessed methodological quality, and extracted data. Selection of studies Four trials met the inclusion criteria, with 169 patients. Main outcome measures Mean change in spirometry, clinical end points, symptom scores, and adverse events. Results Mean change in forced expiratory volume at one second at two hours was similar in methylxanthine and placebo groups but transiently increased with methylxanthines at three days. Non-significant reductions in admissions to hospital and length of stay were offset by a non-significant increase in relapses at one week. Changes in symptom scores did not reach significance. Methylxanthines caused more nausea and vomiting than placebo (odds ratio 4.6, 95% confidence interval 1.7 to 12.6), and non-significant increases in tremor, palpitations, and arrhythmias were also observed. Conclusions The available data do not support the use of methylxanthines for the treatment of exacerbations of chronic obstructive pulmonary disease. Potential benefits of methylxanthines for lung function and symptoms were generally not confirmed at standard levels of significance, whereas the potentially important adverse events of nausea and vomiting were significantly increased in patients receiving methylxanthines.

Doxofylline and Theophylline: A Comparative Clinical Study

“…So, in our study the dose of theophylline sustained release was 400 mg once daily. Theophylline has no role in the acute exacerbation of COPD, it but has a role in the long term management [8][9][10]. So, the sustained release tablets were considered to be clinically more relevant.…”

Acute exacerbation in COPD and asthma

“…Ataklarda metilksantinler, inhale bronkodilatör uygulanan hastalarda ek yarar sağlamamaktadır; buna kar-şılık, sıklıkla bulantı-kusma, çarpıntı ve aritmiye neden olmaktadır (152).…”

Zalecenia Polskiego Towarzystwa Chorób Płuc Dotyczące Rozpoznawania i Leczenia Przewlekłej Obturacyjnej Choroby Płuc

“…W kontrolowanych badaniach klinicznych skojarzone leczenie wGKS i długo działającymi lekami rozszerzającymi oskrzela okazało się bardziej skuteczne w porównaniu zarówno z placebo, jak i z każdym z tych leków stosowanym w monoterapii [90][91][92][93][94][95][96][97][98][99][100][101].…”